vs
豪洛捷（HOLX）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是RANGE RESOURCES CORP的1.3倍（$1.0B vs $786.9M），RANGE RESOURCES CORP净利率更高（22.8% vs 17.1%，领先5.7%），RANGE RESOURCES CORP同比增速更快（18.0% vs 2.5%），过去两年RANGE RESOURCES CORP的营收复合增速更高（14.6% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
HOLX vs RRC — 直观对比
营收规模更大
HOLX
是对方的1.3倍
$786.9M
营收增速更快
RRC
高出15.4%
2.5%
净利率更高
RRC
高出5.7%
17.1%
两年增速更快
RRC
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $786.9M |
| 净利润 | $179.1M | $179.1M |
| 毛利率 | 56.0% | 94.5% |
| 营业利润率 | 22.6% | — |
| 净利率 | 17.1% | 22.8% |
| 营收同比 | 2.5% | 18.0% |
| 净利润同比 | -10.9% | 88.8% |
| 每股收益（稀释后） | $0.79 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRRC
| Q4 25 | $1.0B | $786.9M | ||
| Q3 25 | $1.0B | $655.3M | ||
| Q2 25 | $1.0B | $699.6M | ||
| Q1 25 | $1.0B | $846.3M | ||
| Q4 24 | $1.0B | $667.0M | ||
| Q3 24 | $988.0M | $567.9M | ||
| Q2 24 | $1.0B | $513.2M | ||
| Q1 24 | $1.0B | $598.8M |
净利润HOLXRRC
| Q4 25 | $179.1M | $179.1M | ||
| Q3 25 | $187.2M | $144.3M | ||
| Q2 25 | $194.9M | $237.6M | ||
| Q1 25 | $-17.4M | $97.1M | ||
| Q4 24 | $201.0M | $94.8M | ||
| Q3 24 | $178.6M | $50.7M | ||
| Q2 24 | $194.5M | $28.7M | ||
| Q1 24 | $169.9M | $92.1M |
毛利率HOLXRRC
| Q4 25 | 56.0% | 94.5% | ||
| Q3 25 | 55.6% | 92.5% | ||
| Q2 25 | 56.3% | 95.0% | ||
| Q1 25 | 37.5% | 93.1% | ||
| Q4 24 | 56.8% | 93.7% | ||
| Q3 24 | 56.4% | 94.3% | ||
| Q2 24 | 55.4% | 93.4% | ||
| Q1 24 | 53.3% | 94.7% |
营业利润率HOLXRRC
| Q4 25 | 22.6% | — | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 24.9% | — | ||
| Q1 25 | -0.7% | — | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 23.3% | — | ||
| Q2 24 | 24.1% | — | ||
| Q1 24 | 20.7% | — |
净利率HOLXRRC
| Q4 25 | 17.1% | 22.8% | ||
| Q3 25 | 17.8% | 22.0% | ||
| Q2 25 | 19.0% | 34.0% | ||
| Q1 25 | -1.7% | 11.5% | ||
| Q4 24 | 19.7% | 14.2% | ||
| Q3 24 | 18.1% | 8.9% | ||
| Q2 24 | 19.2% | 5.6% | ||
| Q1 24 | 16.7% | 15.4% |
每股收益（稀释后）HOLXRRC
| Q4 25 | $0.79 | $0.75 | ||
| Q3 25 | $0.84 | $0.60 | ||
| Q2 25 | $0.86 | $0.99 | ||
| Q1 25 | $-0.08 | $0.40 | ||
| Q4 24 | $0.87 | $0.38 | ||
| Q3 24 | $0.75 | $0.21 | ||
| Q2 24 | $0.82 | $0.12 | ||
| Q1 24 | $0.72 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $204.0K |
| 总债务越低越好 | $2.5B | $1.2B |
| 股东权益账面价值 | $5.2B | $4.3B |
| 总资产 | $9.2B | $7.4B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资HOLXRRC
| Q4 25 | $2.4B | $204.0K | ||
| Q3 25 | $2.2B | $175.0K | ||
| Q2 25 | $1.9B | $134.0K | ||
| Q1 25 | $1.6B | $344.6M | ||
| Q4 24 | $2.0B | $304.5M | ||
| Q3 24 | $2.3B | $277.4M | ||
| Q2 24 | $2.4B | $251.1M | ||
| Q1 24 | $2.2B | $343.1M |
总债务HOLXRRC
| Q4 25 | $2.5B | $1.2B | ||
| Q3 25 | $2.5B | $1.2B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.5B | $1.7B | ||
| Q4 24 | $2.5B | $1.7B | ||
| Q3 24 | $2.5B | $1.7B | ||
| Q2 24 | $2.5B | $1.7B | ||
| Q1 24 | $2.6B | $1.8B |
股东权益HOLXRRC
| Q4 25 | $5.2B | $4.3B | ||
| Q3 25 | $5.0B | $4.2B | ||
| Q2 25 | $4.8B | $4.1B | ||
| Q1 25 | $4.6B | $3.9B | ||
| Q4 24 | $4.8B | $3.9B | ||
| Q3 24 | $5.1B | $3.9B | ||
| Q2 24 | $5.0B | $3.9B | ||
| Q1 24 | $4.8B | $3.8B |
总资产HOLXRRC
| Q4 25 | $9.2B | $7.4B | ||
| Q3 25 | $9.0B | $7.2B | ||
| Q2 25 | $8.8B | $7.1B | ||
| Q1 25 | $8.5B | $7.4B | ||
| Q4 24 | $8.7B | $7.3B | ||
| Q3 24 | $9.2B | $7.2B | ||
| Q2 24 | $8.9B | $7.3B | ||
| Q1 24 | $8.7B | $7.4B |
负债/权益比HOLXRRC
| Q4 25 | 0.48× | 0.28× | ||
| Q3 25 | 0.50× | 0.29× | ||
| Q2 25 | 0.52× | 0.29× | ||
| Q1 25 | 0.55× | 0.43× | ||
| Q4 24 | 0.53× | 0.43× | ||
| Q3 24 | 0.49× | 0.44× | ||
| Q2 24 | 0.51× | 0.44× | ||
| Q1 24 | 0.53× | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $257.5M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.4% | — |
| 现金转化率经营现金流/净利润 | 1.28× | 1.44× |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流HOLXRRC
| Q4 25 | $229.9M | $257.5M | ||
| Q3 25 | $355.1M | $247.5M | ||
| Q2 25 | $343.3M | $336.2M | ||
| Q1 25 | $169.4M | $330.1M | ||
| Q4 24 | $189.3M | $217.9M | ||
| Q3 24 | $367.0M | $245.9M | ||
| Q2 24 | $405.8M | $148.8M | ||
| Q1 24 | $292.4M | $331.9M |
自由现金流HOLXRRC
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | — | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | — | ||
| Q2 24 | $385.3M | — | ||
| Q1 24 | $279.6M | — |
自由现金流率HOLXRRC
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 38.1% | — | ||
| Q1 24 | 27.5% | — |
资本支出强度HOLXRRC
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.3% | — |
现金转化率HOLXRRC
| Q4 25 | 1.28× | 1.44× | ||
| Q3 25 | 1.90× | 1.72× | ||
| Q2 25 | 1.76× | 1.42× | ||
| Q1 25 | — | 3.40× | ||
| Q4 24 | 0.94× | 2.30× | ||
| Q3 24 | 2.05× | 4.85× | ||
| Q2 24 | 2.09× | 5.18× | ||
| Q1 24 | 1.72× | 3.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
